VOR Vor Biopharma Inc
Price (delayed)
$0.634
Market cap
$79.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.7
Enterprise value
$26.62M
Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that
Highlights
The debt is down by 11% YoY and by 3.1% from the previous quarter
Vor Biopharma's quick ratio has decreased by 43% YoY but it has increased by 11% from the previous quarter
Vor Biopharma's equity has decreased by 36% YoY but it has increased by 32% from the previous quarter
The net income has contracted by 4% from the previous quarter
Key stats
What are the main financial stats of VOR
Market
Valuations
Earnings
Shares outstanding
124.85M
Market cap
$79.16M
Enterprise value
$26.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.45
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$121.19M
Net income
-$116.91M
EBIT
-$116.91M
EBITDA
-$108.35M
Free cash flow
-$99.89M
Per share
Balance sheet
Liquidity
EPS
-$1.7
EPS diluted
-$1.7
Free cash flow per share
-$1.45
Book value per share
$1.41
Revenue per share
$0
TBVPS
$2.08
Total assets
$142.89M
Total liabilities
$46.23M
Debt
$31.83M
Equity
$96.66M
Working capital
$77.9M
Debt to equity
0.33
Current ratio
5.19
Quick ratio
5.07
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-82.4%
Return on equity
-119.7%
Return on invested capital
-124.6%
Return on capital employed
-94.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VOR stock price
How has the Vor Biopharma stock price performed over time
Intraday
2.26%
1 week
-21.73%
1 month
-41.3%
1 year
-69.67%
YTD
-42.88%
QTD
-11.64%
Financial performance
How have Vor Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$121.19M
Net income
-$116.91M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 4% from the previous quarter
The company's operating income rose by 3.8% YoY but it fell by 2.7% QoQ
Growth
What is Vor Biopharma's growth rate over time
Valuation
What is Vor Biopharma stock price valuation
P/E
N/A
P/B
0.45
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VOR's EPS is down by 3.7% from the previous quarter but it is up by 2.9% YoY
VOR's price to book (P/B) is 73% less than its 5-year quarterly average of 1.6 and 51% less than its last 4 quarters average of 0.9
Vor Biopharma's equity has decreased by 36% YoY but it has increased by 32% from the previous quarter
Efficiency
How efficient is Vor Biopharma business performance
The return on invested capital has dropped by 133% year-on-year and by 35% since the previous quarter
The company's return on equity has shrunk by 93% YoY and by 18% QoQ
The return on assets has dropped by 66% year-on-year and by 14% since the previous quarter
Dividends
What is VOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VOR.
Financial health
How did Vor Biopharma financials performed over time
Vor Biopharma's current ratio has decreased by 43% YoY but it has increased by 11% from the previous quarter
Vor Biopharma's quick ratio has decreased by 43% YoY but it has increased by 11% from the previous quarter
The debt is 67% less than the equity
Vor Biopharma's debt to equity has increased by 38% YoY but it has decreased by 27% QoQ
Vor Biopharma's equity has decreased by 36% YoY but it has increased by 32% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.